Journal Cover Letter Template: 5 Filled-In Examples for Any Journal (2026)
Most cover letters fail because researchers write summaries instead of pitches. Here are 5 complete, filled-in templates for different journal tiers and fields: copy, adapt, submit.
Associate Professor, Clinical Medicine & Public Health
Author context
Specializes in clinical and epidemiological research publishing, with direct experience preparing manuscripts for NEJM, JAMA, BMJ, and The Lancet.
Readiness scan
Find out if this manuscript is ready to submit.
Run the Free Readiness Scan before you submit. Catch the issues editors reject on first read.
How to use this page well
These pages work best when they behave like tools, not essays. Use the quick structure first, then apply it to the exact journal and manuscript situation.
Question | What to do |
|---|---|
Use this page for | A working artifact you can actually apply to the manuscript or response package. |
Start with | Fill the template with real manuscript-specific details instead of leaving it generic. |
Common mistake | Copying the structure without tailoring the logic to the actual submission. |
Best next step | Use the artifact once, then cut anything that does not affect the decision. |
Quick answer:
Writing a cover letter for journal submission should not take more than 30 minutes. If it's taking longer, you are overthinking it.
Editors read hundreds of cover letters. The ones that work lead with the finding, explain why it matters, explain why this journal. Three things. That is it.
Below are five complete, filled-in templates for different journal tiers and fields. Pick the one closest to your situation, swap in your details, and you are done.
What a journal cover letter must include
Every journal cover letter needs these five elements:
- Your finding in one sentence, the main result, stated plainly, not your topic or background
- Why it matters, 2-3 sentences with at least one number (sample size, effect size, p-value)
- Why this journal, name a recent paper from this journal and connect it directly to your work
- Competing interests and logistics, conflicts of interest, data availability, trial registration if applicable
- Author approval, confirm all authors have approved the submission
That is the complete list. A cover letter that hits all five points in under 300 words will outperform a 600-word letter that buries the finding in paragraph three.
Six templates: jump to yours
- Template 1: High-impact multidisciplinary journal (Nature Portfolio, Science family, Cell Press upper tier)
- Template 2: Clinical/medical journal (NEJM, Lancet, JAMA, BMJ)
- Template 3: Mid-tier specialist journal (IF 5-15, field-specific)
- Template 4: Open-access journal (PLOS ONE, Scientific Reports, Frontiers)
- Template 5: Resubmission after invited revision
- Template 6: Resubmitting a rejected paper to a new journal
Use for: Nature Communications, Science Advances, PNAS, Cell Reports, eLife
Dear Editor,
We show that FOXO3a nuclear localization is driven by intracellular calcium flux, not AKT phosphorylation as previously assumed. This finding reframes two decades of work on FOXO3a-mediated apoptosis resistance in solid tumors.
Using live-cell calcium imaging in 12 primary tumor cell lines paired with single-cell transcriptomics, we demonstrate that calcium-dependent FOXO3a activation is necessary and sufficient for doxorubicin resistance. Blocking calcium entry with FDA-approved L-type channel blockers sensitized resistant tumor cells to doxorubicin in both cell culture and mouse xenograft models.
This work builds directly on Zhang et al. (2024, Nature Communications) who identified FOXO3a as a resistance marker but could not explain the activation mechanism. We resolve that question and point to a clinically actionable intervention. We believe this manuscript will interest the broad readership of Nature Communications given its mechanistic depth and immediate translational relevance.
All authors have approved this submission. We have no competing interests. Data and code are deposited at [repository DOI].
Sincerely,
[Name, Institution, email]
Why this works: First sentence states the finding and names the prior assumption it overturns. Second paragraph gives mechanism, evidence type, and animal model. Third paragraph names a specific recent paper from this journal. No filler, no "we are pleased to submit."
Use for: NEJM, Lancet, JAMA, BMJ, Annals of Internal Medicine, Circulation
Dear Editor,
We report a randomized controlled trial demonstrating that a 12-week structured exercise intervention reduces 90-day hospital readmission rates by 34% in patients with moderate-to-severe heart failure (hazard ratio 0.66, 95% CI 0.51-0.85, p=0.001).
Our trial enrolled 847 patients across 14 centers. The intervention is low-cost, scalable, and deliverable by non-specialist staff without specialized equipment. At current US heart failure readmission rates, widespread adoption could prevent approximately 180,000 readmissions annually.
Despite strong evidence for exercise in stable heart failure, benefit in patients with recent decompensation has been uncertain. We recruited exclusively within 30 days of discharge, filling a gap that prior trials, including HF-ACTION, explicitly excluded. We believe this evidence gap is directly relevant to The Lancet's clinical readership.
All authors have approved this submission. The trial is registered at ClinicalTrials.gov (NCT04XXXXXX). We have no competing interests.
Sincerely,
[Name, Institution, email]
Why this works: Clinical editors want numbers in sentence one. Paragraph 2 addresses scalability and public health impact. The gap versus named prior trials is explicit. Trial registration is stated up front.
Template 3: Mid-tier specialist journal (Nature Communications, PNAS)
Use for: journals with IF 5-15 in your specific field
Dear Dr. [Editor name],
We submit our manuscript describing a novel mechanism by which Pseudomonas aeruginosa biofilms evade neutrophil extracellular traps (NETs) via phenazine-mediated DNA degradation. This mechanism has not previously been described and may explain why chronic P. aeruginosa infections persist despite intact innate immune responses.
Using confocal microscopy, genetic knockouts, and a murine lung infection model, we show that phenazine production by biofilm-embedded P. aeruginosa degrades NET DNA within 4 hours of contact, preventing NET-mediated bacterial killing. Phenazine-deficient mutants were 8-fold more susceptible to NET killing than wild-type strains.
The Journal of Infectious Diseases has recently published strong work on biofilm immune evasion (Smith et al. 2024; Chen et al. 2023), and we believe this mechanistic paper adds directly to that body of work.
All authors have approved this submission. The authors declare no competing interests.
Sincerely,
[Name, Institution, email]
Why this works: Specialist editors do not need broad significance explained. Technical terminology is appropriate. Two specific recent papers from this journal are cited. Shorter than Template 1 because specialist journals do not need the same scope justification.
Template 4: Open-access journal (eLife, PLOS ONE, Scientific Reports)
Use for: PLOS ONE, Scientific Reports, BMJ Open, Frontiers journals
Dear Editor,
We submit a methodological validation study of a machine learning algorithm for automated grading of diabetic retinopathy severity from fundus photographs. The algorithm achieves 94.2% sensitivity and 91.8% specificity against a panel of three board-certified ophthalmologists (n=2,847 images from three independent test sets).
The algorithm is trained on publicly available datasets and released under MIT license at [GitHub URL]. Validation includes images from low-resource clinical settings in sub-Saharan Africa, addressing a gap in most published retinopathy AI tools which are validated only on Western clinical data.
We submit to PLOS ONE because this work represents a technically sound, reproducible contribution with clear clinical utility. All data and code are available as described in the data availability statement.
Ethics approval documentation is included in the submission.
Sincerely,
[Name, Institution, email]
Why this works: Leads with performance numbers. Explicitly invokes PLOS ONE's soundness-only review criteria. Addresses data availability proactively. Does not claim novelty it doesn't have.
Template 5: Resubmission after invited revision (see our guide on what to do after desk rejection)
Only use this if the editor explicitly invited resubmission. A form rejection with no invitation means submit elsewhere.
Dear Dr. [Editor name],
We resubmit our manuscript (originally submitted as MS-XXXXX) with substantial revisions in response to your editorial assessment.
We have [describe changes specifically: e.g., added two in vivo validation experiments using the xenograft model you suggested, restructured the main claims to focus on the calcium mechanism rather than the downstream apoptosis pathway, and removed the clinical extrapolations that went beyond our data].
The core finding is unchanged: [one sentence restating the result]. We believe the revised manuscript now addresses the concerns you identified about [specific issue] and is appropriate for [Journal Name].
We have not submitted this manuscript elsewhere during the revision period. All authors have approved this resubmission.
Sincerely,
[Name]
Important: Be specific about what changed. "We have addressed the reviewer comments" without details signals to editors that you have not taken the feedback seriously.
Template 6: Resubmitting a rejected paper to a new journal
Use for: any new submission after a rejection elsewhere. Do NOT mention the previous rejection unless the new journal explicitly asks.
Dear Dr. [Editor name],
We submit our manuscript describing [one-sentence finding]. [Two to three sentences of significance, with numbers.]
[Journal fit paragraph: name a recent paper from this journal, explain the connection to your work.]
All authors have approved this submission. [Competing interests. Data availability.]
Sincerely,
[Name, Institution, email]
The key difference from a fresh submission: There isn't one in the letter itself. You're not obligated to disclose a previous rejection, and doing so unprompted can hurt you. If a journal specifically asks, be honest. If the editor offers a transfer (e.g., Science to Science Advances), the original reviews come with the manuscript and you'll need to address them in the cover letter.
Cover Letter Decision Framework
Journal tier | Cover letter approach | Common mistake |
|---|---|---|
Nature/Science/Cell | Lead with the paradigm shift in sentence 1. Must explain cross-field significance | Opening with "We are pleased to submit..." |
NEJM/Lancet/JAMA | Lead with the practice change. What should physicians do differently? | Arguing for prestige instead of clinical relevance |
Nature Communications/PNAS/Science Advances | Lead with the advance for specialists. Why is this important beyond one subfield? | Recycling a Nature rejection cover letter without reframing |
Specialty journals (IF 4-15) | Lead with the specific contribution to the field conversation | Over-claiming broad significance for a specialist paper |
Megajournals (PLOS ONE, Scientific Reports) | Lead with methodological rigor and data completeness | Trying to sound prestigious when soundness is the bar |
Replace these openings
Replace this | With this |
|---|---|
We are pleased to submit our manuscript entitled... | We show that [finding]. |
Herein we describe our study examining... | Our study demonstrates that [result]. |
We are submitting a manuscript detailing our research into... | We report a [X]% [outcome] using [intervention]. |
The present study investigates the role of X in Y. | X controls Y by mechanism Z, as we show here. |
The first sentence is your best shot at making an editor stop and read the second one. Use it.
Suggested reviewers: how to do it right
Many journals ask for suggested reviewers. Most authors treat this as a box to tick. That's a mistake, suggested reviewers who actually get assigned give faster, more informed reviews.
Who to suggest: People who have published on your topic in the last 3-5 years but are not current or recent collaborators. Mid-career researchers are better choices than famous senior figures, they're more likely to accept the invitation and give a thorough review. Include people from different institutions and countries. Aim for 3-5 names.
What to include: Full name, institution and department, email address (this is what editors actually need), and optionally one sentence on why they're qualified.
Who NOT to suggest: Your PhD supervisor, postdoc mentor, anyone you've co-authored with recently, people at the same institution as any co-author, or very famous researchers who are likely overloaded.
Opposed reviewers: Most journals let you request exclusions for direct competitors with conflicts. Use this for people who have made hostile statements about your work, not just anyone who might be critical.
Submit If / Think Twice If
Submit this cover letter if:
- The first sentence states your actual finding, not your topic, research area, or the fact that you are submitting
- You have at least one number in the first paragraph (sample size, effect size, p-value, or performance metric)
- You have named a specific recent paper from the target journal, not just the journal itself
- The competing interests and data availability statements are addressed
- The letter is under 400 words
Think twice if:
- The letter opens with "We are pleased to submit our manuscript entitled..." (this signals immediately that the finding is buried)
- The journal fit paragraph is generic ("this journal publishes research on X") rather than specific to a recent paper
- There is no number in the first 100 words
- The letter is a summary of the paper's methods rather than a pitch for why the editor should read the paper
- The same letter is being sent to multiple journals without rewriting the journal-fit paragraph
Readiness check
Run the scan to see how your manuscript scores on these criteria.
See score, top issues, and what to fix before you submit.
Before you submit: final checklist
- [ ] First sentence states your finding, not your topic
- [ ] At least one number (sample size, effect size, p-value, or equivalent)
- [ ] You named a specific paper from this journal, not the journal itself
- [ ] Competing interests declared
- [ ] Data availability addressed
- [ ] Under 400 words total
- [ ] Editor addressed by name if you know it
- [ ] No "we are pleased to submit"
What Pre-Submission Reviews Reveal About Cover Letter Failures
In our pre-submission review work with manuscripts targeting journals from Nature Portfolio through Lancet family and specialty journals, three cover letter patterns generate the most consistent desk rejections among the papers we analyze.
The finding buried in paragraph three. Editors at flagship journals read hundreds of cover letters per week. In our review work, we consistently see letters that open with background context, move to methodology in paragraph two, and finally state the finding in paragraph three. By that point, the editor has already formed an impression of the paper's urgency. At journals where editors make initial triage decisions in under two minutes, a letter that buries the finding is functionally a letter that has no finding. The first sentence must state the result, not the motivation for studying the topic.
Journal fit that is generic rather than specific. A persistent failure pattern: cover letters that justify journal fit by describing the journal's general scope ("JAMA publishes clinical research, and our paper addresses a clinical question"). This tells the editor nothing about why this paper belongs in this journal rather than the other five journals that publish clinical research. We find that letters naming a specific recent paper from the target journal and explaining the direct connection to the submitted work are substantially more effective. Editors notice when an author has read the journal carefully enough to identify the right connecting paper. This specificity is rare and therefore signals.
Missing or incorrect logistics. In our analysis of rejected cover letters, a recurring practical failure: competing interest statements that are absent or vague, trial registration numbers not stated up front for clinical trials, and data availability statements deferred to "see the manuscript" without a direct statement in the letter itself. Flagship journals (Nature, Lancet, NEJM, JAMA) have specific requirements for what must appear in the cover letter, separate from the submission system checkboxes. Papers that omit these elements create administrative friction that editors interpret as author inexperience with the journal's expectations.
SciRev author-reported data on review timelines confirms that papers cleared efficiently through editorial triage have cover letters that flag key details immediately, reducing the time editors spend hunting for information before deciding whether to read the paper. A manuscript readiness check includes cover letter feedback as part of the diagnostic.
Elsevier cover letter requirements
Keep under one page. Explain scope fit and emphasize novelty. Do not include funding information, author declarations, or reviewer suggestions, handled separately in submission system.
A manuscript scope and readiness check scores desk-reject risk. The manuscript readiness check verifies citations against 500M+ papers.
Frequently asked questions
Most journals require or strongly recommend cover letters. Even when optional, a good cover letter increases your chances by helping editors understand why your paper matters and fits their journal.
Lead with your main finding (1 sentence), explain significance (2-3 sentences), show journal fit (2 sentences), and close professionally. Keep it under one page.
Be direct: state what you found, why it matters, and why this journal. Skip background they already know. Include specific numbers and avoid generic praise.
Yes, if the journal allows it. Suggest 2-3 mid-career experts who know your field but aren't close collaborators. Include their institution and email. Avoid only suggesting famous people who are too busy to review.
Don't mention the previous rejection unless the new journal asks. Reframe the cover letter entirely for the new journal's scope and readership. If reviewers from the previous journal raised valid concerns you've addressed, you can incorporate those improvements without referencing where they came from.
200-350 words is the sweet spot. Never go over 400. Editors skim cover letters in under a minute, so shorter letters that lead with the finding outperform longer ones that bury it in background.
Yes, if you can find the handling editor's name on the journal website. 'Dear Dr. [Name]' is better than 'Dear Editor' because it shows you've done your homework. If you can't find the name, 'Dear Editors' works fine.
Sources
Reference library
Use the core publishing datasets alongside this guide
This article answers one part of the publishing decision. The reference library covers the recurring questions that usually come next: whether the package is ready, what drives desk rejection, how journals compare, and what the submission requirements look like across journals.
Checklist system / operational asset
Elite Submission Checklist
A flagship pre-submission checklist that turns journal-fit, desk-reject, and package-quality lessons into one operational final-pass audit.
Flagship report / decision support
Desk Rejection Report
A canonical desk-rejection report that organizes the most common editorial failure modes, what they look like, and how to prevent them.
Dataset / reference hub
Journal Intelligence Dataset
A canonical journal dataset that combines selectivity posture, review timing, submission requirements, and Manusights fit signals in one citeable reference asset.
Dataset / reference guide
Peer Review Timelines by Journal
Reference-grade journal timeline data that authors, labs, and writing centers can cite when discussing realistic review timing.
Final step
Find out if this manuscript is ready to submit.
Run the Free Readiness Scan. See score, top issues, and journal-fit signals before you submit.
Anthropic Privacy Partner. Zero-retention manuscript processing.
Where to go next
Supporting reads
Conversion step
Find out if this manuscript is ready to submit.
Anthropic Privacy Partner. Zero-retention manuscript processing.